Cargando…
Cyclophosphamide induces durable molecular and clinical responses in patients with relapsed T-LGL leukemia
Autores principales: | Braunstein, Zachary, McLaughlin, Eric, Mishra, Anjali, Brammer, Jonathan E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043937/ https://www.ncbi.nlm.nih.gov/pubmed/34996100 http://dx.doi.org/10.1182/bloodadvances.2021006263 |
Ejemplares similares
-
Cyclophosphamide as a first-line therapy in LGL leukemia
por: Moignet, A, et al.
Publicado: (2014) -
Florid Pulmonary Mycobacterium avium-intracellulare Infection in a Patient With Large Granular Lymphocytic (LGL) Leukemia on Chronic Cyclophosphamide
por: Kojadinovic, Arsenije, et al.
Publicado: (2021) -
A case of LGL leukemia with paucity of erythropoiesis
por: Razavi, Habib M.
Publicado: (2020) -
A guilt-by-association mutation network in LGL leukemia
por: Andersson, Emma I., et al.
Publicado: (2017) -
Retrovirus insertion site analysis of LGL leukemia patient genomes
por: Li, Weiling, et al.
Publicado: (2019)